Enrichment of elevated plasma F2t-isoprostane levels in individuals with autism who are stratified by presence of gastrointestinal dysfunction

Phillip Gorrindo, Christianne Joy Lane, Evon Batey Lee, Bethann McLaughlin, Pat Levitt, Phillip Gorrindo, Christianne Joy Lane, Evon Batey Lee, Bethann McLaughlin, Pat Levitt

Abstract

Etiology is unknown in the majority of individuals with autism spectrum disorder (ASD). One strategy to investigate pathogenesis is to stratify this heterogeneous disorder based on a prominent phenotypic feature that enriches for homogeneity within population strata. Co-occurring gastrointestinal dysfunction (GID) characterizes a subset of children with ASD. Our current objective was to investigate a potential pathophysiological measure to test the hypothesis that children with both ASD and GID have a more severe metabolic dysfunction than children with ASD-only, given that the highly metabolically active brain and gastrointestinal system may additively contribute measurable impairment. Plasma levels of F2t-Isoprostanes (F2-IsoPs), a gold standard biomarker of oxidative stress, were measured in 87 children in four groups: ASD-GID, ASD-only, GID-only and Unaffected. F2-IsoP levels were elevated in all 3 clinical groups compared to the Unaffected group, with the ASD-GID group significantly elevated above the ASD-only group (mean, SD in pg/mg: ASD-GID 53.6, 24.4; ASD-only 36.5, 13.3; p = 0.007). Adjusting for age, sex, and triglyceride levels, F2-IsoP levels remained significantly different between study groups, with a moderate effect size of η(p)(2) = 0.187 (p = 0.001). Elevation in peripheral oxidative stress is consistent with, and may contribute to, the more severe functional impairments in the ASD-GID group. With unique medical, metabolic, and behavioral features in children with ASD-GID, the present findings serve as a compelling rationale for both individualized approaches to clinical care and integrated studies of biomarker enrichment in ASD subgroups that may better address the complex etiology of ASD.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Plasma F 2t -Isoprostane levels…
Figure 1. Plasma F2t-Isoprostane levels among four study groups.
Data are plotted as mean (SD). Open circles are female participants; closed circles are male participants.

References

    1. State MW, Levitt P (2011) The conundrums of understanding genetic risks for autism spectrum disorders. Nature Neuroscience 14: 1–8.
    1. Berg JM, Geschwind DH (2012) Autism genetics: search for specificity and convergence. Genome Biology 13: 247–263.
    1. Constantino JN, Todorov A, Hilton C, Law P, Zhang Y, et al... (2012) Autism recurrance in half siblings: strong support for genetic mechanisms of transmission in ASD. Molecular Psychiatry e-ahead of print.
    1. Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, et al. (2012) Common genetic variants, acting additively, are a major source of risk for autism. Mol Autism 3: 9.
    1. Rudie JD, Hernandez LM, Brown JA, Beck-Pancer D, Colich NL, et al... (2012) Autism-associated promoter varient in MET impacts functional and structural brain networks. Neuron In Press.
    1. Campbell DB, Buie TM, Winter H, Bauman M, Sutcliffe JS, et al. (2009) Distinct Genetic Risk Based on Association of MET in Families With Co-occurring Autism and Gastrointestinal Conditions. PEDIATRICS 123: 1018–1024.
    1. Geschwind DH (2009) Advances in autism. Annual review of medicine 60: 367–380.
    1. Rice K, Moriuchi JM, Jones W, Klin A (2012) Parsing heterogeneity in autism spectrum disorders: visual scanning of dynamic social scenes in school-aged children. J Am Acad Child Adolesc Psychiatry 51: 238–248.
    1. Lu AT-H, Cantor RM (2010) Allowing for sex differences increases power in a GWAS of multiplex Autism families. Molecular Psychiatry.
    1. Scott-Van Zeeland AA, Abrahams BS, Alvarez-Retuerto AI, Sonnenblick LI, Rudie JD, et al. (2009) Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2. Science Translational Medicine 2: 1–6.
    1. Buie T, Campbell DB, Fuchs GJ, 3rd, Furuta GT, Levy J, et al (2010) Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 125 Suppl 1S1–18.
    1. Black C, Kaye JA, Jick H (2002) Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ (Clinical research ed) 325: 419–421.
    1. Molloy CA, Manning-Courtney P (2003) Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism: the international journal of research and practice 7: 165–171.
    1. Levy SE, Souders MC, Ittenbach RF, Giarelli E, Mulberg AE, et al. (2007) Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biological Psychiatry 61: 492–497.
    1. Valicenti-McDermott M, McVicar K, Rapin I, Wershil BK, Cohen H, et al. (2006) Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr 27: S128–136.
    1. Ibrahim SH, Voigt RG, Katusic SK, Weaver AL, Barbaresi WJ (2009) Incidence of gastrointestinal symptoms in children with autism: a population-based study. PEDIATRICS 124: 680–686.
    1. Wang LW, Tancredi DJ, Thomas DW (2011) The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. J Dev Behav Pediatrics 32: 351–360.
    1. Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, et al. (2012) Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. Autism Res 5: 101–108.
    1. Buie TM, Fuchs GJ, Furuta GT, Kooros K, Levy J, et al. (2010) Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs. PEDIATRICS 125 Suppl 1S19–29.
    1. Oliveira G, Diogo L, Grazina M, Garcia P, Ataíde A, et al. (2005) Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Developmental medicine and child neurology 47: 185–189.
    1. Giulivi C, Zhang Y-F, Omanska-Klusek A, Ross-Inta C, Wong S, et al. (2010) Mitochondrial dysfunction in autism. JAMA: the journal of the American Medical Association 304: 2389–2396.
    1. Anney RJL, Kenny EM, O'Dushlaine C, Yaspan BL, Parkhomenka E, et al... (2011) Gene-ontology enrichment analysis in two independent family-based samples highlights biologically plausible processes for autism spectrum disorders. European journal of human genetics: EJHG.
    1. Bowers K, Li Q, Bressler J, Avramopoulos D, Newschaffer C, et al. (2011) Glutathione pathway gene variation and risk of autism spectrum disorders. Journal of Neurodevelopmental Disorders 3: 132–143.
    1. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, et al. (2006) Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 141B: 947–956.
    1. Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, et al. (2011) Metabolic Imbalance Associated with Methylation Dysregulation and Oxidative Damage in Children with Autism. Journal of Autism and Developmental Disorders
    1. Milne GL, Sanchez SC, Musiek ES, Morrow JD (2007) Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nature protocols 2: 221–226.
    1. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, et al. (2005) Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free radical biology & medicine 38: 698–710.
    1. Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, et al. (2005) Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free radical biology & medicine 38: 711–718.
    1. Cracowski J-L, Bonaz B, Bessard G, Bessard J, Anglade C, et al. (2002) Increased urinary F2-isoprostanes in patients with Crohn's disease. The American journal of gastroenterology 97: 99–103.
    1. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, et al. (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney international 65: 1009–1016.
    1. Zeiger SLH, Musiek ES, Zanoni G, Vidari G, Morrow JD, et al. (2009) Neurotoxic lipid peroxidation species formed by ischemic stroke increase injury. Free radical biology & medicine 47: 1422–1431.
    1. Walker LS, Caplan-Dover A, Rasquin-Weber A (2000) Manual for the Questionnaire on Pediatric Gastrointestinal Symptoms.
    1. Drossman DA (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130: 1377–1390.
    1. Constantino JN, Todd RD (2003) Autistic traits in the general population: a twin study. Arch Gen Psychiatry 60: 524–530.
    1. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, et al. (2003) Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 33: 427–433.
    1. Albers E, Donahue BS, Milne G, Saville BR, Wang W, et al. (2012) Perioperative plasma F(2)-Isoprostane levels correlate with markers of impaired ventilation in infants with single-ventricle physiology undergoing stage 2 surgical palliation on the cardiopulmonary bypass. Pediatr Cardiol 33: 562–568.
    1. Morrow JD, Roberts LJ 2nd (1999) Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 300: 3–12.
    1. Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, et al. (2009) HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 50: 716–722.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, et al. (2009) Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377–381.
    1. Gotham K, Risi S, Pickles A, Lord C (2007) The Autism Diagnostic Observation Schedule: revised algorithms for improved diagnostic validity. J Autism Dev Disord 37: 613–627.
    1. Baber KF, Anderson J, Puzanovova M, Walker LS (2008) Rome II versus Rome III classification of functional gastrointestinal disorders in pediatric chronic abdominal pain. J Pediatr Gastroenterol Nutr 47: 299–302.
    1. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, et al. (2008) Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 39: 100–104.
    1. Ming X, Stein T, Brimacombe M, Johnson W, Lambert G, et al. (2005) Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins, Leukotrienes and Essential Fatty Acids 73: 379–384.
    1. Yao Y, Walsh WJ, McGinnis WR, Praticò D (2006) Altered vascular phenotype in autism: correlation with oxidative stress. Archives of neurology 63: 1161–1164.
    1. Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B, et al. (2011) Normal gut microbiota modulates brain development and behavior. Proceedings of the National Academy of Sciences 108: 3047–3052.
    1. Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13: 701–712.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅